Revvity Secures FDA Clearance for Innovative Free Testosterone Testing Assay
- Revvity received FDA clearance for the first automated test to directly quantify free testosterone levels.
- The new test offers rapid results and high-throughput capabilities, enhancing diagnostic efficiency for healthcare facilities.
- Revvity emphasizes innovation in health sciences, maintaining a strong global presence and commitment to emerging healthcare needs.
Revvity Achieves Milestone in Testosterone Testing with FDA Clearance
Revvity, Inc. announces a significant advancement in diagnostic testing following the U.S. Food and Drug Administration's (FDA) 510(k) clearance for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This test stands out as the first FDA-cleared assay capable of directly quantifying free testosterone levels, marking a pivotal development in endocrinology diagnostics. The innovative test utilizes advanced chemiluminescence technology to deliver rapid results, with initial outputs available in just 48 minutes and an impressive throughput of nearly 60 tests per hour.
The assay’s design incorporates monoclonal antibodies, ensuring both specificity and consistent performance across different test batches. This technological enhancement not only improves the accuracy of testosterone measurements but also facilitates high-throughput testing on EUROIMMUN’s random-access iSYSTM and i10 TM instruments. As a result, laboratories can expect quick turnaround times while requiring minimal technician training, making this test user-friendly and accessible for a wide range of healthcare facilities. The introduction of this assay significantly bolsters diagnostic capabilities for conditions such as hypogonadism, impotence, and polycystic ovarian syndrome (PCOS), which are critical for patient management and treatment.
Jonathan Friend, general manager at Revvity’s EUROIMMUN US, emphasizes that this FDA clearance directly responds to the needs of laboratory customers for a reliable and efficient test. With over 11,000 employees and projected revenues exceeding $2.7 billion in 2023, Revvity continues to demonstrate its commitment to innovation in health sciences. The company’s focus on translational multi-omics technologies, biomarker identification, and diagnostics positions it as a key player in the global health landscape, serving diverse sectors including pharmaceutical, biotech, academia, and government.
In addition to this groundbreaking testing advancement, Revvity maintains a robust global presence, operating in more than 190 countries and being a member of the S&P 500 index. This strategic positioning allows the company to continually respond to emerging healthcare needs and technological advancements. For additional insights into EUROIMMUN's diagnostic solutions, stakeholders and interested parties can access information through the company’s website.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

